A Study of the Value of Trio Genome Sequencing in the Etiological Evaluation of Early-Onset and/or Atypical Psychiatric Disorders Without Intellectual Disability or Congenital Anomalies (PSYGEN)
According to the World Health Organization, one in eight people worldwide has a mental disorder, defined as a significant impairment in thinking, emotional regulation, or behavior. These disorders are classified according to the DSM-5. These psychiatric disorders may be atypical in terms of their age of onset, course of the illness, unusual response to treatment, or classification (significant impact but classified as a "disorder not otherwise specified" by the DSM-5). These disorders can occur sporadically or run in families.
In France, there are no genetic testing recommendations for these patients. A CGH-array analysis may be ordered as part of patient care, as may testing for Fragile X syndrome, depending on the clinical context.
The main hypothesis is that atypical psychiatric disorders result from multifactorial inheritance, involving a combination of common genetic variations and environmental factors. Pangenomic association studies and twin studies have already demonstrated heritability in these psychiatric disorders. It has now been shown that some neurodevelopmental disorders (NDDs) and psychiatric disorders-such as autism spectrum disorders or schizophrenia, for which similar hypotheses were proposed in the past-may result from monogenic inheritance. Furthermore, preliminary indications now allow for the prescription of genome sequencing on the platforms of the France Genomic Medicine Plan 2025.
To date, no study has evaluated the role of high-throughput sequencing in an etiological approach to atypical, non-syndromic psychiatric disorders. Through this study, we aim to assess whether genome sequencing (GS) could be relevant for atypical, non-syndromic psychiatric disorders, which would be the case if it leads to an etiological diagnosis in at least 12% of cases.
The establishment of the GénoPsy network (Centers of Excellence for Behavioral Disorders in Developmental Disorders) creates an environment that is highly conducive to the development of this project.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Caroline RACINE
- Telefonnummer: +33 03.80.29.53.13
- E-post: caroline.racine@chu-dijon.fr
Studiesteder
-
-
-
Dijon, Frankrike, 21000
- CHU Dijon Bourgogne
-
Ta kontakt med:
- Caroline RACINE
- Telefonnummer: +33 03.80.29.53.13
- E-post: caroline.racine@chu-dijon.fr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Index case with one or more psychiatric disorders confirmed by a psychiatrist and/or child psychiatrist, whose evaluations may be supplemented as needed as part of their care, and who meets at least ONE of the following criteria for atypicality:
- Early age of onset
- Unusual course of the disorder (polymorphic/fluctuating)
- Treatment resistance
- Disorder classified as "unspecified" by the DSM-5 with significant functional impact
- Index case aged 3 to 50 years, inclusive
- Consent signed by the biological parents and by the "index case, if of legal age"
- Index case and their parents enrolled in or eligible for a social security program
- Sample collection possible from the index case and their two known biological parents
Exclusion Criteria:
- Genetic testing previously performed (CGH array, targeted gene testing, gene panel, etc.)
- Parent(s) and/or the index case subject to a court-ordered protective measure
- The index case and his or her parents have a condition that, in the investigator's opinion, would contraindicate the subject's participation in the study
- Presence of an intellectual developmental disorder confirmed by a neuropsychological test or strongly suspected clinically in the index case and/or their parents
- Index case with a clear syndromic diagnosis
- Index case with a psychiatric disorder already covered by a pre-indication under PFMG2025.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
The index case and his two parents
Index cases with one or more psychiatric disorders
|
Collection of an EDTA blood sample from the index case and his or her two biological parents
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Identification of at least one likely pathogenic or pathogenic variant (ACMG classification class 4/5) responsible for a condition that explains the patient(s psychiatric symptoms.
Tidsramme: 8 months
|
8 months
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- RACINE PHRCI 2023
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .